Generate Biomedicines (GENB) investor relations material

Vision and platform strategy

• Focus on programmable biology to create transformative medicines beyond the reach of traditional technologies.

• Integrated computational and biohardware innovation stack enables intentionality at scale in drug design.

• Platform leverages machine learning, proprietary data cycles, and high-throughput biohardware for rapid, precise protein engineering.

• Strategic collaborations with Amgen, Novartis, MD Anderson, and Roswell Park expand platform reach.

• Demonstrated ability to reduce drug discovery time and cost, with 8 programs reaching candidate nomination and 5 clinical/clinic-ready candidates.

Pipeline and clinical programs

• Five clinical-stage or clinic-ready molecules, including GB-0895 (anti-TSLP mAb), GB-4362 (MMAE toxin neutralizer), and GB-5267 (MUC16 CAR-T).

• GB-0895 is the first next-gen anti-TSLP mAb to enter global Phase 3, with twice-annual dosing and the longest known human half-life among TSLP therapies.

• GB-4362 targets toxicity of MMAE-based ADCs, aiming to reduce peripheral neuropathy and expand ADC use.

• GB-5267 is an IL-18 armored CAR-T for platinum-resistant ovarian cancer, designed to overcome solid tumor barriers.

• Multiple preclinical programs and confidential collaborations with major pharma partners.

Clinical data and differentiation

• GB-0895 Phase 1 showed sustained biomarker reductions and a ~98-day half-life, supporting direct progression to Phase 3.

• Single 300mg dose of GB-0895 over 6 months achieved similar biomarker reductions as monthly 210mg tezepelumab over 12 months.

• Safety profile for GB-0895 was favorable, with low ADA rates and no impact on PK or half-life.

• GB-4362 preclinical data demonstrated reduction of MMAE toxicity without impacting anti-tumor efficacy.

• GB-5267 preclinical models showed superior tumor killing and persistence compared to clinical CARs.